11/15
03:26 pm
ppbt
Purple Biotech Ltd (NASDAQ: PPBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $33.00 price target on the stock.
Low
Report
Purple Biotech Ltd (NASDAQ: PPBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $33.00 price target on the stock.
11/15
07:06 am
ppbt
Purple Biotech Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
Purple Biotech Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
11/15
07:00 am
ppbt
Purple Biotech Reports Third Quarter 2024 Financial Results
Low
Report
Purple Biotech Reports Third Quarter 2024 Financial Results
11/4
07:50 am
ppbt
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
Medium
Report
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
10/25
07:20 am
ppbt
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Medium
Report
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
10/10
07:30 am
ppbt
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Medium
Report
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
9/20
02:17 pm
ppbt
Purple Biotech Ltd (NASDAQ: PPBT) had its price target raised by analysts at HC Wainwright from $8.00 to $33.00. They now have a "buy" rating on the stock.
Low
Report
Purple Biotech Ltd (NASDAQ: PPBT) had its price target raised by analysts at HC Wainwright from $8.00 to $33.00. They now have a "buy" rating on the stock.
9/18
06:30 am
ppbt
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
Medium
Report
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
9/10
07:00 am
ppbt
Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
Low
Report
Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
8/30
07:00 am
ppbt
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
Medium
Report
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference